share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  06/21 16:33
Moomoo AI 已提取核心訊息
On June 18, 2024, Allarity Therapeutics, Inc. received notification from the Nasdaq Listing Qualifications Staff that the company is not in compliance with the Nasdaq Listing Rule 5550(a)(2), due to its common stock bid price falling below the $1 per share minimum requirement for 30 consecutive business days. The company plans to appeal this by requesting a hearing before a Nasdaq Hearings Panel to seek continued listing while it works to regain compliance. The filing of the hearing request will postpone the suspension of trading and potential delisting of the company's common stock until the Panel reaches a decision. Allarity Therapeutics has cautioned that there is no guarantee the Panel will allow the company to remain listed on the Nasdaq Capital Market.
On June 18, 2024, Allarity Therapeutics, Inc. received notification from the Nasdaq Listing Qualifications Staff that the company is not in compliance with the Nasdaq Listing Rule 5550(a)(2), due to its common stock bid price falling below the $1 per share minimum requirement for 30 consecutive business days. The company plans to appeal this by requesting a hearing before a Nasdaq Hearings Panel to seek continued listing while it works to regain compliance. The filing of the hearing request will postpone the suspension of trading and potential delisting of the company's common stock until the Panel reaches a decision. Allarity Therapeutics has cautioned that there is no guarantee the Panel will allow the company to remain listed on the Nasdaq Capital Market.
2024年6月18日,Allarity Therapeutics公司收到納斯達克上市資格工作人員的通知,由於其普通股買盤價格連續30個工作日低於每股1美元的最低要求,公司不符合納斯達克上市規則5550(a)(2)。公司計劃請求納斯達克聽證委員會的聽證會,以尋求繼續上市,同時努力恢復符合要求。提出聽證請求會推遲交易暫停和可能的股票退市,直到委員會做出決定。Allarity Therapeutics公司警告稱,沒有保證委員會會允許公司繼續在納斯達克資本市場上市。
2024年6月18日,Allarity Therapeutics公司收到納斯達克上市資格工作人員的通知,由於其普通股買盤價格連續30個工作日低於每股1美元的最低要求,公司不符合納斯達克上市規則5550(a)(2)。公司計劃請求納斯達克聽證委員會的聽證會,以尋求繼續上市,同時努力恢復符合要求。提出聽證請求會推遲交易暫停和可能的股票退市,直到委員會做出決定。Allarity Therapeutics公司警告稱,沒有保證委員會會允許公司繼續在納斯達克資本市場上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息